Hi all
Not sure if anybody has put this up yet, but thought I'd share my high level notes on MSB's cash forecast without taking into account any revenue from Temcell:
Opening Balance December 2016 = US$33.9m
MNK January 2017 = +US$21.7m
Placement March 2017 = +US$40.0m
Q3 cash outflow = -US$27.0m
Forecast March17 = US$68.6m
Aust Gov rebate = +US$5.0m
Q4 cash outflow = -US$27.0m
Forecast June17 = US$46.6m
FY18 Q1 outflow = -US$27.0m
**MNK deal = +US$XXXm?
Forecast Sep17=US$19.6m +US$XXXm?
Other than the MNK deal, here are the potential sources of material cash injections throughout 2017/early 2018:
- Temcell sales ramping up
- Japan/China deal on RA/CLBP/CHF (can be approved on P2 data)
- RA partner (US)
- CHF partner (US)
- Priority review voucher (aGVHD); potentially worth tens or US$100+ million.
Mesoblast cash forecast
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |